A step towards informed positioning of advanced therapies for moderate-to-severe Crohn's disease.

[1]  M. Murad,et al.  Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. , 2021, The lancet. Gastroenterology & hepatology.

[2]  D. Rubin,et al.  775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study , 2021, Gastroenterology.

[3]  B. Sands,et al.  OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study , 2021 .

[4]  B. Sands,et al.  Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies , 2020, Inflammatory bowel diseases.

[5]  M. Murad,et al.  Systematic review and network meta‐analysis: first‐ and second‐line biologic therapies for moderate‐severe Crohn's disease , 2018, Alimentary pharmacology & therapeutics.

[6]  T. Matsui,et al.  Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. , 2016, Journal of Crohn's & colitis.

[7]  A. Gottlieb,et al.  Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). , 2015, Journal of drugs in dermatology : JDD.

[8]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[9]  S. Hanauer,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab , 2007, Annals of Internal Medicine.